{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:59:35Z","timestamp":1772164775771,"version":"3.50.1"},"reference-count":41,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>As survival rates for lymphoid malignancies continue to improve, understanding the late effects after treatment, such as secondary myeloid neoplasms (sMN), is increasingly critical for survivorship. This large-scale population-based (SEER-Medicare) study investigated the risk factors and cumulative incidence of sMNs in patients with diagnosis of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma between 2000 and 2011, with follow-up through 2015. Patients with FL had a continuous increase in the cumulative incidence of sMNs with longer follow-up, whereas incidence of patients with multiple myeloma plateaued after 60 months. Notably, patients with DLBCL diagnosed in more recent years (2004\u20132007 and 2008\u20132011) had a higher cumulative sMN incidence compared with those diagnosed earlier (2000\u20132003). In the Medicare population, older age at diagnosis was associated with significant increase in sMN risk in patients with DLBCL and FL. Chemotherapy exposure or G-CSF exposure significantly increased sMN risk across all three malignancies. Chronic autoimmune conditions increased sMN risk in patients with DLBCL. These findings provide crucial insights into sMN risk factors. Chemotherapy exposure is a recognized risk factor, and comorbidities such as a history of autoimmunity and G-CSF exposures have been identified as additional mediators of sMN risk in our study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Our study reveals population-level risk factors for sMNs, including novel links to autoimmune disease and G-CSF, in addition to known causes like chemotherapy\/radiation. These findings underscore the complex pathogenesis of sMNs and the need for molecular data in prospective studies to guide prevention, detection, and survivorship care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0340","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:19:01Z","timestamp":1763137141000},"page":"2149-2156","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk Factors beyond Chemotherapy Exposure for Secondary Myeloid Neoplasms after Hematologic Cancers: A SEER-Based Study"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6657-8647","authenticated-orcid":false,"given":"Abhay","family":"Singh","sequence":"first","affiliation":[{"name":"1Department of Hematology Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-8855","authenticated-orcid":false,"given":"Theresa","family":"Hahn","sequence":"additional","affiliation":[{"name":"2Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5631-1164","authenticated-orcid":false,"given":"Rahul","family":"Mishra","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, Anne Arundel Medical Center, Annapolis, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4216-1414","authenticated-orcid":false,"given":"Swapna","family":"Thota","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, University of Tennessee Health Science Center, Memphis, Tennessee."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"2025121102034716900_bib1","doi-asserted-by":"crossref","first-page":"23284","DOI":"10.1038\/s41598-021-02497-4","article-title":"Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States","volume":"11","author":"Singh","year":"2021","journal-title":"Sci Rep"},{"key":"2025121102034716900_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.beha.2019.02.008","article-title":"Therapy-related myeloid neoplasms in lymphoma survivors: reducing risks","volume":"32","author":"Al-Juhaishi","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"2025121102034716900_bib3","doi-asserted-by":"crossref","first-page":"102060","DOI":"10.1016\/j.eclinm.2023.102060","article-title":"Trends in risk for therapy-related myelodysplastic syndrome\/acute myeloid leukemia after initial chemo\/immunotherapy for common and rare lymphoid neoplasms, 2000\u20132018","volume":"61","author":"Morton","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025121102034716900_bib4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/biomedicines12051054","article-title":"Therapy-related myeloid neoplasm: biology and mechanistic aspects of malignant progression","volume":"12","author":"Travaglini","year":"2024","journal-title":"Biomedicines"},{"key":"2025121102034716900_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025121102034716900_bib6","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s41375-024-02258-y","article-title":"Clonal hematopoiesis\u2013derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders","volume":"38","author":"Awada","year":"2024","journal-title":"Leukemia"},{"key":"2025121102034716900_bib7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.seminhematol.2024.01.006","article-title":"The crossroads of cancer therapies and clonal hematopoiesis","volume":"61","author":"Singh","year":"2024","journal-title":"Semin Hematol"},{"key":"2025121102034716900_bib8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2025121102034716900_bib9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"2025121102034716900_bib10","first-page":"128","article-title":"From clonal hematopoiesis to therapy-related myeloid neoplasms: the silent way of cancer progression","volume":"10","author":"Gurnari","year":"2021","journal-title":"Biology (Basel)"},{"key":"2025121102034716900_bib11","doi-asserted-by":"crossref","first-page":"e2100309","DOI":"10.1200\/PO.21.00309","article-title":"Mutant PPM1D- and TP53-driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy","volume":"6","author":"Singh","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2025121102034716900_bib12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2025121102034716900_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jnci\/djk028","article-title":"Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy","volume":"99","author":"Hershman","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2025121102034716900_bib14","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.2009.25.8723","article-title":"Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review","volume":"28","author":"Lyman","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025121102034716900_bib15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.6004\/jnccn.2011.0077","article-title":"Long-term outcomes of myeloid growth factor treatment","volume":"9","author":"Lyman","year":"2011","journal-title":"J Natl Compr Cancer Netw"},{"key":"2025121102034716900_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1365-2141.1998.01014.x","article-title":"Long-term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults","volume":"103","author":"Kaito","year":"1998","journal-title":"Br J Haematol"},{"key":"2025121102034716900_bib17","doi-asserted-by":"crossref","first-page":"107584","DOI":"10.1016\/j.leukres.2024.107584","article-title":"Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: case series and literature review","volume":"146","author":"Mishra","year":"2024","journal-title":"Leuk Res"},{"key":"2025121102034716900_bib18","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.leukres.2013.04.007","article-title":"Myelodysplastic syndromes and autoimmune diseases\u2013case series and review of literature","volume":"37","author":"Al Ustwani","year":"2013","journal-title":"Leuk Res"},{"key":"2025121102034716900_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.seminhematol.2024.01.012","article-title":"Clonal hematopoiesis and autoimmunity","volume":"61","author":"Kishtagari","year":"2024","journal-title":"Semin Hematol"},{"issue":"Suppl 16","key":"2025121102034716900_bib20","doi-asserted-by":"crossref","first-page":"11164","DOI":"10.1200\/JCO.2024.42.16_suppl.11164","article-title":"Therapy-related myeloid neoplasm risk score (TMNRS): a convenient clinical score for TMN risk assessment at presentation in adult patients (pts) with cancer","volume":"42","author":"Singh","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2025121102034716900_bib21","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2023-187424","article-title":"Can emergency hematopoiesis due to sepsis lead to clonal hematopoiesis? Implications for understanding the pathogenesis of clonal evolution","volume":"142","author":"Ogbue","year":"2023","journal-title":"Blood"},{"issue":"Suppl 16","key":"2025121102034716900_bib22","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1200\/JCO.2023.41.16_suppl.7010","article-title":"Identification and management of clonal hematopoiesis of indeterminate potential (CHIP) in cancer survivors: the Cleveland Clinic experience","volume":"41","author":"Kuzmanovic","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025121102034716900_bib23","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"2025121102034716900_bib24","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3324\/haematol.2022.281724","article-title":"Clonal hematopoiesis in diffuse large B-cell lymphoma: clinical impact and genetic relatedness to lymphoma and therapy-related myeloid neoplasm","volume":"108","author":"Liu","year":"2023","journal-title":"Haematologica"},{"key":"2025121102034716900_bib25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025121102034716900_bib26","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2007-01-067769","article-title":"The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma","volume":"110","author":"Park","year":"2007","journal-title":"Blood"},{"key":"2025121102034716900_bib27","doi-asserted-by":"crossref","first-page":"1073274818789355","DOI":"10.1177\/1073274818789355","article-title":"Immortal time bias in observational studies of time-to-event outcomes: assessing effects of postmastectomy radiation therapy using the National Cancer Database","volume":"25","author":"Agarwal","year":"2018","journal-title":"Cancer Control"},{"key":"2025121102034716900_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminhematol.2024.01.002","article-title":"Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence","volume":"61","author":"Pagliuca","year":"2024","journal-title":"Semin Hematol"},{"key":"2025121102034716900_bib29","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.19.01937","article-title":"Impaired immune health in survivors of diffuse large B-cell lymphoma","volume":"38","author":"Shree","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025121102034716900_bib30","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.clml.2017.11.009","article-title":"Characterizing autoimmune disease-associated diffuse large B-cell lymphoma in a SEER\u2013Medicare cohort","volume":"18","author":"Koff","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025121102034716900_bib31","doi-asserted-by":"crossref","first-page":"e178722","DOI":"10.1172\/JCI178722","article-title":"Estimation of prevalence of autoimmune diseases in the United States using electronic health record data","volume":"135","author":"Abend","year":"2025","journal-title":"J Clin Invest"},{"key":"2025121102034716900_bib32","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1002\/cam4.3237","article-title":"Recent survival trends in diffuse large B-cell lymphoma\u2013have we made any progress beyond rituximab?","volume":"9","author":"Epperla","year":"2020","journal-title":"Cancer Med"},{"key":"2025121102034716900_bib33","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.clml.2017.08.098","article-title":"Pegylated GCSF can be used with first-line da-EPOCH-R without compromising dose intensity, safety, or efficacy","volume":"17","author":"Reddy","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025121102034716900_bib34","doi-asserted-by":"crossref","first-page":"100757","DOI":"10.1016\/j.blre.2020.100757","article-title":"Second primary malignancies in multiple myeloma: a review","volume":"46","author":"Poh","year":"2021","journal-title":"Blood Rev"},{"key":"2025121102034716900_bib35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/ejh.13650","article-title":"Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma","volume":"107","author":"Jonsdottir","year":"2021","journal-title":"Eur J Haematol"},{"key":"2025121102034716900_bib36","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1182\/blood.V126.23.3989.3989","article-title":"Life expectancy in follicular lymphoma is mainly determined by response to first LINE treatment: a LONG-TERM Survey on 597 patients","volume":"126","author":"Tarella","year":"2015","journal-title":"Blood"},{"key":"2025121102034716900_bib37","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clml.2017.06.028","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a United States population-based study","volume":"17","author":"Giri","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025121102034716900_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00707-4","article-title":"Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma","volume":"12","author":"Alkhateeb","year":"2022","journal-title":"Blood Cancer J"},{"issue":"Suppl 1","key":"2025121102034716900_bib39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2023-182522","article-title":"CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias","volume":"142","author":"Hamilton","year":"2023","journal-title":"Blood"},{"key":"2025121102034716900_bib40","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1158\/1078-0432.CCR-25-1587","article-title":"Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy","volume":"31","author":"Avigan","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"2025121102034716900_bib41","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2022-159973","article-title":"Risk factors beyond chemo-radiotherapy exposure for therapy-related myelodysplastic syndrome (tMDS) and acute myeloid leukemia (tAML) development in breast cancer survivors: a 15-year SEER-Medicare analysis","volume":"140","author":"Singh","year":"2022","journal-title":"Blood"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0340\/3670633\/crc-25-0340.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/12\/2149\/3714788\/crc-25-0340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/12\/2149\/3714788\/crc-25-0340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T07:03:56Z","timestamp":1765436636000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/12\/2149\/770874\/Risk-Factors-beyond-Chemotherapy-Exposure-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0340","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30857637","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30857649","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30857661","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30857640","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30857652","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30857643","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30857655","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30857634","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30857646","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30857658","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8197032","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}